β细胞替代治疗1型糖尿病的研究进展

doi:10.3969/j.issn.1004-583X.2021.08.018

摘要/Abstract

摘要：

治疗1型糖尿病的主要目标是通过胰岛素注射控制血糖,以降低并发症发生。在胰岛素输注技术不足、有严重低血糖症或已接受肾脏移植治疗后服用免疫抑制的患者,启用β细胞替代治疗是一种安全且有效的治疗手段。其中同种异体胰岛移植是主要方法之一,肝内胰岛移植已被证实可以有效缓解上述不稳定1型糖尿病负担,有效预防糖尿病相关的急慢性并发症(包括曾进行过肾脏移植的患者)。患者的年龄、BMI、肾脏功能和心肺功能均会影响胰腺或胰岛移植的疗效,移植途径则受到胰腺细胞供者的数量和是否需要使用免疫抑制剂的限制。未来β细胞替代治疗的方法包括异种组织或人干细胞,肝外植入(例如网膜、皮下或肌内),诱导免疫耐受以及胰岛微包囊技术。

中图分类号:

R587.1

杨静静, 戎成振, 蒋影, 曹秀菁. β细胞替代治疗1型糖尿病的研究进展[J]. 临床荟萃, 2021, 36(8): 761-764.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.08.018

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I8/761

参考文献 28

[1]	Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen[J]. N Engl J Med, 2000, 343(4):230-238. doi: 10.1056/NEJM200007273430401 URL
[2]	Hering BJ, Clarke WR, Bridges ND, et al. Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia[J]. Diabetes Care, 2016, 39(7):1230-1240. doi: 10.2337/dc15-1988 URL
[3]	Lablanche S, Vantyghem MC, Kessler L, et al. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): A ulticentre, randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2018, 6(7):527-537. doi: 10.1016/S2213-8587(18)30078-0 URL
[4]	Rickels MR, Peleckis AJ, Markmann E, et al. Long-term improvement in glucose control and counterregulation by islet transplantation for type 1 diabetes[J]. J Clin Endocrinol Metab, 2016, 101(11):4421-4430. doi: 10.1210/jc.2016-1649 URL
[5]	胡安斌, 凌象超, 段金良, 等. 同种异体胰岛移植治疗成人晚期糖尿病早期疗效观察[J]. 中华医学杂志, 2020, 100(26):2040-2043.
[6]	Fensom B, Harris C, Thompson SE, et al. Islet cell transplantation improves nerve conduction velocity in type 1 diabetes compared with intensive medical therapy over six years[J]. Diabetes Res Clin Pract, 2016, 122:101-105. doi: 10.1016/j.diabres.2016.10.011 URL
[7]	Holmes-Walker DJ, Gunton JE, Hawthorne W, et al. Islet transplantation provides superior glycemic control with less hypoglycemia compared with continuous subcutaneous insulin infusion or multiple daily insulin injections[J]. Transplantation, 2017, 101(6):1268-1275. doi: 10.1097/TP.0000000000001381 pmid: 27490410
[8]	Kumar AF, Gruessner RW, Seaquist ER. Risk of glucose intolerance and diabetes in hemipancreatectomized donors selected for normal preoperative glucose metabolism[J]. Diabetes Care, 2008, 31(8):1639-1643. doi: 10.2337/dc07-2453 URL
[9]	Ricordi C, Goldstein JS, Balamurugan AN, et al. National Institutes of Health-sponsored Clinical Islet Transplantation Consortium phase 3 trial: Manufacture of a complex cellular product at eight processing facilities[J]. Diabetes, 2016, 65(11):3418-3428. doi: 10.2337/db16-0234 URL
[10]	张博雅, 张静楠, 裴广辉, 等. 门静脉内胰岛移植对受者转氨酶水平的影响因素分析[J]. 中华器官移植杂志. 2019, 40(9):519-522.
[11]	Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes[J]. JAMA, 2005, 293(7): 830, 835.
[12]	Estrada EJ, Decima JL, Bortman G, et al. Combination treatment of autologous bone marrow stem cell transplantation and hyperbaric oxygen therapy for type 2 diabetes mellitus: A randomized controlled trial[J]. Cell Transplant, 2019, 28(12):1632-1640. doi: 10.1177/0963689719883813 URL
[13]	Ye L, Li L, Wan B, et al. Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus[J]. Stem Cell Res Ther, 2017, 8(1):90-95. doi: 10.1186/s13287-017-0542-1 URL
[14]	Nijhoff MF, Engelse MA, Dubbeld J, et al. Glycemic stability through islet-after-kidney transplantation using an alemtuzumab-based induction regimen and long-term triple-maintenance immunosuppression[J]. Am J Transplant, 2016, 16(1):246-253. doi: 10.1111/ajt.13425 pmid: 26288226
[15]	Perdigoto AL, Preston-Hurlburt P, Clark P, et al. Treatment of type 1 diabetes with teplizumab: Clinical and immunological follow-up after 7 years from diagnosis[J]. Diabetologia, 2019, 62(4):655-664. doi: 10.1007/s00125-018-4786-9 pmid: 30569273
[16]	Takita M, Matsumoto S, Shimoda M, et al. Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation[J]. Clin Transplant, 2012, 26(5):471-484.
[17]	Huurman VA, Hilbrands R, Pinkse GG, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation[J]. PLoS One, 2008, 3(6):e2435. doi: 10.1371/journal.pone.0002435 URL
[18]	Pepper AR, Bruni A, Pawlick R, et al. Post-transplant characterization of long-term functional hESC-derived pancreatic endoderm grafts[J]. Diabetes, 2019, 68(5):953-962. doi: 10.2337/db18-0788 URL
[19]	焦自钊, 薛武军, 安茂竹, 等. 联合移植的脂肪间充质干细胞对胰岛移植物功能及生存的影响[J]. 中华器官移植杂志, 2019, 4(7): 428, 433.
[20]	Millman JR, Xie C, Van Dervort A, et al. Generation of stem cell-derived β-cells from patients with type 1 diabetes[J]. Nat Commun, 2016, 7:11463. doi: 10.1038/ncomms11463. doi: 10.1038/ncomms11463 URL
[21]	Sui L, Danzl N, Campbell SR, et al. β-Cell replacement in mice using human type 1 diabetes nuclear transfer embryonic stem cells[J]. Diabetes, 2018, 67(1):26-35. doi: 10.2337/db17-0120 URL
[22]	Salama BF, Seeberger KL, Korbutt GS. Fibrin supports subcutaneous neonatal porcine islet transplantation without the need for pre-vascularization[J]. Xenotransplantation, 2020, 27(4):e12575.
[23]	程宇, 周丁华, 闫涛, 等. 大鼠肠系膜与肾被膜下移植胰岛治疗糖尿病的疗效对比[J]. 暨南大学学报. 2019, 40(2):157-164.
[24]	刘国涛, 郭栋, 刘全达, 等. 胃浆膜下层与门静脉胰岛移植治疗糖尿病大鼠的实验研究[J]. 中国现代医学杂志, 2018, 28(11):5-9.
[25]	Pellegrini S, Cantarelli E, Citro A, et al. Selective local irradiation mproves islet engraftment and survival in intra-bone marrow islet transplantation[J]. Cytotherapy, 2019, 21(10):1025-1032. doi: S1465-3249(19)30821-7 pmid: 31444049
[26]	Posselt AM, Szot GL, Frassetto LA, et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade[J]. Transplantation, 2010, 90(12):1595-1601. doi: 10.1097/TP.0b013e3181fe1377 pmid: 20978464
[27]	Ludwig B, Ludwig S, Steffen A, et al. Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes[J]. Proc Natl Acad Sci USA, 2017, 114(44):11745-11750. doi: 10.1073/pnas.1708420114 URL
[28]	李传贵, 宋亚军, 杨加彩, 等. 探讨γδT细胞在小鼠胰岛移植排斥反应中的作用[J]. 重庆医学, 2018, 47(13):1705-1708.

β细胞替代治疗1型糖尿病的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 7

编辑推荐

Metrics

本文评价

[1]	杨毅;李蓬秋;王利;鲜杨;张学军;包明晶;张磊. 2型糖尿病患者葡萄糖耐量试验后胰高糖素样肽1水平变化[J]. 临床荟萃, 2014, 29(5): 509-511.
[2]	李玉兰;赖璐华;黄振宇. 初诊2型糖尿病患者基础C肽分泌功能的临床影响因素分析[J]. 临床荟萃, 2013, 28(11): 1261-1263.
[3]	陈睿;陈莉明;常宝成;单春艳;于珮. 2 型糖尿病肾病患者胰岛β细胞功能的研究[J]. 临床荟萃, 2009, 24(6): 522-524.
[4]	杨敏;孙刚;万莹. 甘精胰岛素联合格列齐特缓释片治疗老年2型糖尿病的疗效及β细胞功能的变化[J]. 临床荟萃, 2009, 24(21): 1909-1910.
[5]	程飞;康慨;李莹. 妊娠期不同糖代谢状态胰岛素抵抗和胰岛β细胞分泌功能的临床分析[J]. 临床荟萃, 2009, 24(10): 881-882.
[6]	李玉兰. 初诊2型糖尿病β细胞功能特点及临床干预研究进展[J]. 临床荟萃, 2009, 24(1): 88-90.
[7]	何胜彬;冯小凤;李浩平;郭志强;梁俊文;麦婉婵;覃丽明;梁栋伟. 初诊2型糖尿病32例短期持续皮下输注胰岛素强化降糖治疗对胰岛β细胞功能的影响[J]. 临床荟萃, 2008, 23(24): 1783-1784.